Many cardiomyopathy families have genetic variants whose significance is unknown. We studied a novel (E848G) mutation in MYH7, a sarcomeric protein. 
H eart failure affects w5 million Americans (1) , and two-thirds of the cases are associated with systolic dysfunction (2) . Recent advances in genetic testing have identified mutations in >30 genes as causes for systolic dysfunction, with many of these genes encoding proteins within the cardiac sarcomere (3) . Despite advances in our understanding of genetic cardiomyopathies, the tools to study these diseases are imperfect. Primary human cardiomyocytes are difficult to obtain and maintain in culture. Traditional mouse models are limited, because the electrical and contractile properties are significantly different to allow for a resting heart rate that is 10-fold higher than in humans. Studies involving b-myosin heavy chain (MYH7) in mice are particularly difficult, as the predominant myosin isoform in mice is a-myosin heavy chain (MYH6).
Human induced pluripotent stem cells (hiPSCs)
provide a model to circumvent many of these issues by allowing genetic diseases to be studied in a human context. Recent studies using patient-specific iPSCderived cardiomyocytes (iPSC-CMs) from individuals with various diseases such as long QT syndrome, Brugada syndrome, hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM) have recapitulated many features of the human disease and have advanced our knowledge of the pathophysiology in human cells (4, 5) .
Although iPSC technology is promising, it
can be difficult to model genetic cardiac diseases that have their onset in adulthood due to the immaturity of iPSC-CMs. In addition, proving that a novel variant causes the disease can be difficult using statistical genetics when only small kindreds are available. In the current study, we encountered both of these challenges when studying an African-American familial cardiomyopathy (FCM) with adult-onset systolic dysfunction associated with a rare MYH7 E848G variant (rs727504311). This variant is not described in large population databases such as the Exome Aggregation Consortium or the Genome Aggregation Database but has recently been described by the ClinVar database as "likely pathogenic" (6) . Although contractile deficits were not apparent in early iPSC-CMs carrying the E848G allele, when cells were matured by prolonged culture time or via tissue engineering, their contractile deficits were readily apparent. Using genetic editing and viral transgenesis, we established that MYH7 with the E848G mutation reduces contractile function in a dominant-negative manner, and we provided evidence that a reduced ability to bind cardiac myosin-binding protein C (cMyBP-C) may contribute to the contractile dysfunction. Institutes of Health grants P01 HL094374, R01HL128362, R01 HL084642, P01 GM081619, and U01 HL100405 (to Dr. Murry). This work was also supported by National Institutes of Health grants R01HL135143 to Drs. Kim and Murry and R01 HL111197 and R01 HL128368 to Dr. Regnier. Dr. Yang was supported by grant T32HL007828 from the National Heart, Lung, and Blood Institute and a Bruce-Laughlin Research Fellowship. Dr. Kim is a co-founder and scientific advisor of NanoSurface. Dr.
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METHODS
Details of the materials and methods are available in the Supplemental Material. Briefly, all patient recruitments followed the protocol approved by the institutional review board. Dermal fibroblasts from FCM and normal healthy patients were episomally reprogrammed to iPSCs and differentiated into cardiomyocytes with our well-established monolayer differentiation protocol (7) . Patient-specific iPSC-CMs were replated as single cells or in a three-dimensional co-culture to form engineered heart tissues (EHTs) to assess contractile function. The Clustered Regularly Interspaced Short Palindromic Repeats/CRISPRAssociated Protein 9 system was used to knock out MYH7 (MYH7 KO) to create an isogenic iPSC line.
Yeast two-hybrid analysis was used to test the protein-protein interaction between MYH7 S2 and cMyBP-C C1C2 domains. Yang et al. This mutation occurs at a residue conserved from mouse to humans (Supplemental Table 3 To assess whether the differences in fractional shortening were due to changes in calcium handling, calcium transients were measured by using the ratiometric dye fura-2 with the IonOptix system.
Despite the differences in fractional shortening seen in day 50 FCM-CMs, no difference was observed in maximal intracellular calcium, maximal rate of
Systolic Cardiomyopathy due to MYH7 E848G Posts were designed to be 5 mm apart to form loops on either end of the EHT ( Figure 3B ). Constructs were conditioned with static external stress for 2.5 to 3
weeks to increase cellular alignment and hypertrophy. Interestingly, EHTs with WT hiPSC-CMs exhibited significantly greater cardiomyocyte alignment than did those from FCM hiPSC-CMs (p < 0.05) ( Figures 3C to 3E ).
To study isometric contractile function of the patient-specific EHTs, the loops in the EHTs were mounted between a force transducer and a rod whose position was precisely controlled by a length Yang et al. Quantitative analysis of cytoskeletal alignment of EHTs conditioned with static stress. Vector of stress conditioning is parallel to EHT edge (horizontal). *p < 0.05 (Student's t-test). Error bars indicate SEM. Yang et al. Yang et al.
As expected for a negative control, no growth was seen with unfused BD and AD peptides ( Figure 6A ), whereas the positive control ( Figure 6B) and S2 WT -AD and S2 WT -BD resulted in robust growth, confirming S2 homodimerization ( Figure 6C) . Interestingly, the S2 E848G -AD and S2 WT -BD condition did not have any growth, indicating that the E848G mutation weakens the dimerization of myosin S2 ( Figure 6D ). S2 WT -AD and C1C2 WT -BD resulted in growth, confirming the interactions between MYH7 and cMyBP-C ( Figure 6E ). The S2 WT -AD and C1C2 E258K -BD combination did not have any growth, confirming that this mutation in cMyBP-C prevents its binding to the WT S2 domain ( Figure 6F ) (12) . The key finding of this yeast-two hybrid experiment, however, was the lack of growth with the S2 E848G -AD and C1C2 WT -BD fusion proteins ( Figure 6G ). As expected, the doublemutation experiment involving S2 E848G -AD and C1C2 E258K -BD did not result in any growth ( Figure 6H ). Taken together, these experiments support the hypothesis that the E848G mutation results in disruption of the myosin S2 and cMyBP-C C1C2 protein-protein interaction. Overall, we report a unique cardiomyopathy due to MYH7 E848G mutation that clinically does not clearly fit a diagnosis of HCM or DCM. Recent research suggests that myosin variants that destabilize the myosin interacting heads motif and prevent the superrelaxed state predispose to HCM, whereas mutations that affect the motor domain lead to DCM (27) . MYH7 E848G affects neither: it is not predicted to affect the interacting heads motif or the motor domain. However, our data nevertheless strongly suggest that this is a pathogenic variant that leads to adult-onset, nondilated, nonhypertrophied systolic cardiomyopathy, potentially due to disruption of the MYH7 S2 and cMyBP-C C1C2 protein-protein interaction.
CONCLUSIONS
Overall, patient-specific iPSC-CMs from a family with MYH7 E848G-induced systolic dysfunction along with isogenic control subjects recapitulate the contractile dysfunction that is characteristic of this cardiomyopathy. We predict that other mutations which result in a disruption of the S2:C1C2 interaction will also exhibit a similar phenotype, and that restoration of the protein-protein interaction would prove therapeutic. Systolic Cardiomyopathy due to MYH7 E848G 739
